Code Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2801 Sterling Dr, Hatfield, Pennsylvania...Phone Number
(215) 996-3006Website
www.codebiotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Code Bio
Code Bio founded in 2020, for patients suffering from debilitating genetic diseases, Code Bios novel non-viral gene delivery platform offers new hope for meaningful gene therapy solutions, across numerous indications, that are titratable, have the potential to be re-disable, and able to address diseases with mutations in large genes, headquartered in Philadelphia, PA.Explore more
Code Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Code Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Code Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Code Bio has new funding data
Check if Code Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Code Bio launches new products
Check out if Code Bio is spiking on competitors!
Earning: See what the market has to say on Code Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Code Bio
Click to see if Code Bio had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Code Bio as Masked Content
Find 2 more new buyers
Compare Similar Companies to Code Bio
Compare insights from companies similar to Code Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Code Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Code Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Code Bio.
Code Bio financials insights
Gather financial insights about Code Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$10M
2022
Series A
$75M
Code Bio Tech Stack
A closer look at the technologies used by Code Bio
See more technologies
Most Recent Scoops
Award
Award
Left Company
Executive Move
New Hire
Executive Move
Code Bio has announced that Alex Tracy has joined the organization as Chief Technical Officer. Previously, Tracy served as Chief Technical Officer for BridgeBio.
New Hire
Executive Move
Code Bio has announced that David Anderson has joined the company as Chief Scientific Officer. Previously, Dr. Anderson served as Senior Vice President of Research for SwanBio Therapeutics.
Executive Moves
Funding
Code Bio News & Media
Code Biotherapeutics Names David Anderson, PhD, as Chief Scientific Officer
PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Scientific Officer. “I am thrilled to welcome Dave to the team at this exciting stage of the company’s growth,” said Brian P. McVeigh, Code Bio Co-Founder, Chairman, and Chief Executive Officer. “Dave’s leadership and his extensive experience of successfully progressing mCode Biotherapeutics' $75 Million Series A Financing - Global Legal Chronicle
Morrison Foerster advised New Enterprise Associates, 4BIO Capital, and UPMC Enterprises on the deal. New Enterprise Associates, 4BIO Capital, and UPMC Enterprises acted as investors in …Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases
GREATER PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and oversubscribed Series A financing of $75 million to advance programs to treat and cure rare and prevalent genetic diseases. Northpond Ventures led the financing round with participation from Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors New Enterprise AssocCode Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases
GREATER PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications. Through the agreement, Takeda and Code Bio will design and develop a targeted gene therapy leveraging Co
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Code Bio
Sign Up For FreeTo access detailed company insights
Code Bio founded in 2020, for patients suffering from debilitating genetic diseases, Code Bios novel non-viral gene delivery platform offers new hope for meaningful gene therapy solutions, across numerous indications, that are titratable, have the potential to be re-disable, and able to address diseases with mutations in large genes, headquartered... Read More
